News

Soliris May Be Best Immunotherapy for MG Patients, Study Suggests

Soliris (eculizumab) may be the most effective and well-tolerated immunotherapy for patients with myasthenia gravis (MG), according to an analysis of multiple studies. The research, “Immunosuppressive and monoclonal antibody treatment for myasthenia gravis: A network meta‐analysis,” was published in the journal CNS Neuroscience…

Vienna to Host RARE2019 Meeting on Rare Diseases

About 100 scientists, researchers, pharmaceutical executives, and others will converge on Austria’s capital city early next month for the 2nd International Congress on Advanced Treatments in Rare Diseases. The March 4-5 meeting, to take place at the Hilton Am Stadtpark Vienna, features 27 speakers on a variety of disorders…